Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PS-341 (Bortezomib) in Advanced Renal Cell Carcinoma
NCT00017329Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2001
- Primary completion
- Apr 2004
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in renal cell carcinoma (RCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2001; status: completed.
02
Drugs
bortezomib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00017329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017329.